Education
About Us
Working with TipRanks
Follow Us
Carisma Therapeutics, Inc. (GB:0IFZ)
:0IFZ
RESEARCH TOOLSreports
Total Valuation
Carisma Therapeutics has a market cap or net worth of $22.91M. The enterprise value is $46.45M.
Market Cap$22.91M
Enterprise Value$46.45M
Share Statistics
Carisma Therapeutics has 41,788,097 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding41,788,097
Owned by Insiders1.43%
Owned by Institutions5.52%
Financial Efficiency
Carisma Therapeutics’s return on equity (ROE) is 2.17 and return on invested capital (ROIC) is -347.82%.
Return on Equity (ROE)2.17
Return on Assets (ROA)-1.99
Return on Invested Capital (ROIC)-347.82%
Return on Capital Employed (ROCE)-4.32
Revenue Per Employee426.78K
Profits Per Employee-1.31M
Employee Count46
Asset Turnover0.64
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Carisma Therapeutics is -0.29. Carisma Therapeutics’s PEG ratio is >-0.01.
PE Ratio-0.29
PS Ratio0.00
PB Ratio-3.54
Price to Fair Value-0.62
Price to FCF-2.51
Price to Operating Cash Flow-2.52
PEG Ratio>-0.01
Income Statement
In the last 12 months, Carisma Therapeutics had revenue of 19.63M and earned -60.48M in profits. Earnings per share was -1.46.
Revenue19.63M
Gross Profit16.28M
Operating Income-62.18M
Pretax Income-60.48M
Net Income-60.48M
EBITDA-58.83M
Earnings Per Share (EPS)-1.46
Cash Flow
In the last 12 months, operating cash flow was -47.56M and capital expenditures -94.00K, giving a free cash flow of -47.66M billion.
Operating Cash Flow-47.56M
Free Cash Flow-47.66M
Free Cash Flow per Share-1.14
Dividends & Yields
Carisma Therapeutics pays an annual dividend of $0.361, resulting in a dividend yield of ―
Dividend Per Share$0.361
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.00
52-Week Price Change0.00%
50-Day Moving Average65.80
200-Day Moving Average65.80
Relative Strength Index (RSI)100.00
Average Volume (3m)0.00
Important Dates
Carisma Therapeutics upcoming earnings date is Aug 7, 2025, TBA Not Confirmed.
Last Earnings DateMay 8, 2025
Next Earnings DateAug 7, 2025
Ex-Dividend DateMar 08, 2023
Financial Position
Carisma Therapeutics as a current ratio of 1.48, with Debt / Equity ratio of 0.00%
Current Ratio1.48
Quick Ratio1.48
Debt to Market Cap0.10
Net Debt to EBITDA0.27
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Carisma Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Carisma Therapeutics EV to EBITDA ratio is -0.03, with an EV/FCF ratio of -0.03.
EV to Sales0.10
EV to EBITDA-0.03
EV to Free Cash Flow-0.03
EV to Operating Cash Flow-0.03
Balance Sheet
Carisma Therapeutics has $7.74M in cash and marketable securities with $2.33M in debt, giving a net cash position of -$5.42M billion.
Cash & Marketable Securities$7.74M
Total Debt$2.33M
Net Cash-$5.42M
Net Cash Per Share-$0.13
Tangible Book Value Per Share-$0.67
Margins
Gross margin is 0.00%, with operating margin of -316.72%, and net profit margin of -308.05%.
Gross Margin0.00%
Operating Margin-316.72%
Pretax Margin-308.05%
Net Profit Margin-308.05%
EBITDA Margin-290.97%
EBIT Margin-316.72%
Analyst Forecast
The average price target for Carisma Therapeutics is $1.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$1.00
Price Target Upside-98.48% Downside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast―